Chemistry: molecular biology and microbiology – Micro-organism – per se ; compositions thereof; proces of... – Bacteria or actinomycetales; media therefor
Reexamination Certificate
2007-09-11
2007-09-11
Hayes, Robert C. (Department: 1649)
Chemistry: molecular biology and microbiology
Micro-organism, per se ; compositions thereof; proces of...
Bacteria or actinomycetales; media therefor
C536S023400, C435S320100
Reexamination Certificate
active
10765580
ABSTRACT:
The present invention is directed to an isolated nucleic acid encoding a fusion protein comprising (1) the A subunit of Shiga-like bacterial toxin, or a truncated or mutated version thereof; and (2) human vascular endothelial growth factor, or a truncated or mutated version thereof; wherein the fusion protein possesses ribosome inactivating activity and ability to bind to cellular VEGF receptors. The present invention is also directed to polypeptides the above combination of toxin and growth factor, as well as expression vectors and transformed cells incorporating the above nucleic acid. The invention is also directed to pharmaceutical compositions and methods for treating patients suffering from diseases relating to angiogenesis.
REFERENCES:
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6037329 (2000-03-01), Baird et al.
“Hypoxic Regulation of Vascular Endothelial Growth Factor in Retinal Cells”, Aiello et al.,Arch/Ophthalmol., vol. 113, pp. 1538-1544, 1995.
Cytotoxicity of a Shiga Toxin A Subunit-CD4 Fusion Protein to Human Imunodeficiency Virus-Infected Cells, Al-Jaufy et al.,Infection and Immunity, vol. 62, No. 3, pp. 956-960, 1994.
“Purification and Characterization of a Shiga Toxin A Subunit-CD4 Fusion Protein Cytotoxic to Humman Immunodeficiency Virus-Infected Cells”, Al-Jaufy et al.,Infection and Immunity, vol. 63, No. 8, pp. 3073-3078, 1995.
“Vascular Endothelial Growth Factor Chimeric Toxin Is Highly Active against Endothelial Cells”, Arora et al.,Cancer Research, vol. 59, pp. 183-188, 1999.
“Molecular and Cellular Cardiology/Gene Transfer: Accelerated Restitution of Endothelial Integrity and Endothelium-Dependent Function After pvVEGF sub 165 Gene Transfer”, Takayuki et al.,Ovid: Ashara: Circulation, vol. 94 (12), pp. 3291-3302, 1996.
“Interaction of Vasculotropin/Vascular Endothelial Cell Growth Factor With Human Umbilical Vein Endothelial Cells: Binding, Internalization, Degradation, and Biological Effects”, Bikfalvi et al.,Journal of Cellular Physiology, vol. 149, pp. 50-59, 1991.
“Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Kidney and Bladder Carcinomas”, Brown et al.,American Journal of Pathology, vol. 143, No. 5, pp. 1255-1262, 1993.
“Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer”, Brown et al.,Human Pathology, vol. 26, pp. 86-91, No. 1, 1995.
“Construction of Mutant Genes for a Non-Toxic Verotoxin 2 Variant (VT2vp1) ofEscherichia coliand Characterization of Purified Mutant Toxins”, Cao et al.,Microbiol. Immunol., 38(6), pp. 441-447, 1994.
“Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis”, Claffey et al.,Cancer and Metastasis Review, 15, pp. 165-176, 1996.
“Vascular Endothelial Growth Factor/Vascular Permeability Factor (VEGF/VPF) in Normal and Atherosclerotic Human Arteries”, Couffinhal et al.,American Journal of Biology, vol. 150, No. 5, pp. 1673-1685, 1997.
“The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin 1 A-chain”, Deresiewicz et al.,Mol. Gen. Genet, vol. 241, pp. 467-473, 1993.
“Overexpression of Vascular Permeability Factor/ Vascular Endothelial Growth Factor and its Receptors in Psoriasis”, Detmar et al.,J. Exp. Med., vol. 180, pp. 1141-1146, 1994.
“Angiogenesis”, Folkman et al.,The Journal of Biological Chemistry, vol. 267, No. 16, pp. 10931-10934, 1992.
“Angiogenesis in cancer, vascular, rheumatoid and other disease”, Folkman,Nature Medicine, vol. 1, pp. 27-31, 1995.
“Minimum Domain of the Shiga Toxin A Subunit Required for Enzymatic Activity”, Haddad et al.,Journal of Bacteriology, vol. 175, No. 16, pp. 4970-4978, 1993.
“Signaling Vascular Morphogenesis and Maintenance”, Hanahan,Science, vol. 277(5322), pp. 48-50, 1997.
“Ribotoxic Street Response: Activation of the Stress-Activated Protein Kinase NK1 by Inhibitors of the Peptidyl Transferase Reaction and by Sequence-Specific RNA Damage to the α-Sarcin/Ricin Loop in the 28S rRNa”, Jordanov et al.,Molecular and Cellular Biology, vol. 17, No. 6, pp. 3373-3381, 1997.
“Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes”, Kaplan et al.,Pediatric Nephrology, vol. 4, pp. 276-283, 1990.
“Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo”, Kim et al.,Nature, vol. 362, pp. 841-844, 1993.
“Giloblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant”, Millauer et al.,Nature, vol. 367, pp. 576-579, 1994.
“Vascular Endothelial Growth Factor And Its Receptors”, Neufeld et al.,Process in Growth Factor Research, vol. 5, pp. 89-97, 1994.
“Vascular endothelial growth factor (VEGF) and its receptors”, Neufeld et al.,The FASEB Journal, vol. 13, pp. 9-22, 1999.
“Targeting The Tumor Vasculature: Inhibition Of Tumor Growth By A Vascular Endothelial Growth Factor Toxin Conjugate”, Olson et al.,Int. J. Cancer, vol. 73, pp. 865-870, 1997.
“Endothelial Heterogeneity in Shiga Toxin Receptors and Responses”, Obrig et al.,The Journal of Biological Chemistry, vol. 268, No. 21, pp. 15484-15488, 1993.
“Pathogenesis of Haemolytic Uraemic Syndrome”, Obrig et al.,The Lancet, p. 687, Sep. 1987.
“Up-Regulation of Vascular-Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis”, Plate et al.,Cancer Research, vol. 53, pp. 5822-5827, 1993.
“Vascular Endothelial Growth Factor-Toxin Conjugate Specifically InhibitsKDR/flk-1-positive Endothelial Cell Proliferation in Vitro and Angiogenesis in Vivo”, Ramakrishnan et al.,Cancer Research, vol. 56, pp. 1324-1330, 1996.
“The Histopathology of the Hemolytic Uremic Syndrome Associated with Verocytotoxin-ProducingEscherichia-coliinfections”, Richardson et al.,Human Pathology, vol. 19, No. 9, pp. 1103-1108, 1988.
“Inhibition of Growth of C6 Glioma Cells in Vivo by Expression of Antisense Vascular Endothelial Growth Factor Sequence”, Saleh et al.,Cancer Research, vol. 56, pp. 393-401, 1996.
“Shiga Toxin, Shig-like Toxin II Variant, and Ricin Are All Single-site RNAN-Glycosidases of 28 S RNA When Microinjected intoXenopusOocytes”, Saxena et al.,The Journal of Biological Chemistry, vol. 264, No. 1, pp. 596-601, 1989.
“Biological properties of VEGF/VPF receptors”, Terman et al.,Cancer and Metastasis Reviews, vol. 15, pp. 159-163, 1996.
“Renal dysfunction accounts for the dose limiting toxicity of DT390ati-CD#sFv, a potential new recombinant anti-GVHD immunotoxin”, Vallera et al.,Protein Engineering, vol. 10, No. 9, pp. 1071-1076, 1997.
“VEGFs, a receptor and angiogenesis”, Veikkola et al.,Cancer Biology, vol. 9, pp. 211-220, 1999.
“The RNA-N-Glycosidase Activity of Shiga-Like Toxin I: Kinetic Parameters of the Native and Activated Toxin9”, Brigotti et al.,Toxicom, vol. 35, No. 9, pp. 1431-1437, 1997.
M. V. Backer, et al., “Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery”,National Library of Medicine, vol. 26, No. 3, pp. 455-461, 2002.
M. V. Backer, et al., “Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins”,National Library of Medicine, vol. 12, No. 6, pp. 1066-1073, 2001.
M. V. Backer, et al., “Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2,”National Library of Medicine, vol. 74, No. 1-3, pp. 349-355, 2001.
Backer Joseph M.
Backer Marina V.
Galletta Elizabeth A.
Garabedian Todd E.
Hayes Robert C.
SibTech, Inc.
Wiggin and Dana LLP
LandOfFree
Nucleic acids encoding recombinant proteins containing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding recombinant proteins containing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding recombinant proteins containing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736213